Literature DB >> 22454102

Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer.

Charles C L Tong1, Johnny Kao, Andrew G Sikora.   

Abstract

The estimated annual incidence of oral cavity and pharyngeal cancer is 39,000 in the United States and 260,000 cases worldwide. Despite significant advances in surgery, chemotherapy and radiotherapy, the 5-year survival rate for locally advanced head and neck tumors remains at 50 %. With further intensification of existing treatment limited by the already significant morbidity of multi-modality treatment, there is a clear need for novel therapeutic strategies [1]. Accumulating evidence suggests that the tumor microenvironment of head and neck squamous cell carcinoma (HNSCC) is highly immunosuppressive, mediated by soluble and cell-associated inhibitory mediators and recruitment of host immunosuppressive cells. Thus, understanding and reversing the specific mechanisms underlying tumor-mediated immunosuppression in HNSCC is an important approach to generating an effective antitumor immune response, either as a component of immune-based therapy or as a complement to conventional treatment approaches. This article outlines significant immune-suppressive mechanisms in the HNSCC tumor microenvironment and potential approaches to enhancing the antitumor immune response.

Entities:  

Mesh:

Year:  2012        PMID: 22454102     DOI: 10.1007/s12026-012-8306-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  94 in total

Review 1.  Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.

Authors:  Augusto C Ochoa; Arnold H Zea; Claudia Hernandez; Paulo C Rodriguez
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

2.  Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial.

Authors:  Annelinde Terlou; Manon van Seters; Patricia C Ewing; Neil K Aaronson; Chad M Gundy; Claudia Heijmans-Antonissen; Wim G V Quint; Leen J Blok; Marc van Beurden; Theo J M Helmerhorst
Journal:  Gynecol Oncol       Date:  2011-01-15       Impact factor: 5.482

3.  Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.

Authors:  Yulia Nefedova; Srinivas Nagaraj; Amsler Rosenbauer; Carlos Muro-Cacho; Said M Sebti; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

4.  Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically.

Authors:  G Cortesina; A De Stefani; M Giovarelli; M G Barioglio; G P Cavallo; C Jemma; G Forni
Journal:  Cancer       Date:  1988-12-15       Impact factor: 6.860

5.  Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study.

Authors:  Marina T van Leeuwen; Angela C Webster; Margaret R E McCredie; John H Stewart; Stephen P McDonald; Janaki Amin; John M Kaldor; Jeremy R Chapman; Claire M Vajdic; Andrew E Grulich
Journal:  BMJ       Date:  2010-02-11

6.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 7.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

8.  Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients.

Authors:  G N King; C M Healy; M T Glover; J T Kwan; D M Williams; I M Leigh; H V Worthington; M H Thornhill
Journal:  N Engl J Med       Date:  1995-04-20       Impact factor: 91.245

Review 9.  Ifosfamide in the treatment of head and neck cancer.

Authors:  M Airoldi; G Cortesina; C Giordano; F Pedani; C Bumma
Journal:  Oncology       Date:  2003       Impact factor: 2.935

10.  Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies?

Authors:  Camillo Porta; Chiara Paglino; Ilaria Imarisio; Carlo Ganini; Paolo Pedrazzoli
Journal:  J Cancer       Date:  2011-06-02       Impact factor: 4.207

View more
  26 in total

Review 1.  Hydrogels and scaffolds for immunomodulation.

Authors:  Ankur Singh; Nicholas A Peppas
Journal:  Adv Mater       Date:  2014-08-25       Impact factor: 30.849

2.  DUSP1 phosphatase regulates the proinflammatory milieu in head and neck squamous cell carcinoma.

Authors:  Xiaoyi Zhang; J Madison Hyer; Hong Yu; Nisha J D'Silva; Keith L Kirkwood
Journal:  Cancer Res       Date:  2014-10-13       Impact factor: 12.701

3.  CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma.

Authors:  Guang-Tao Yu; Lin-Lin Bu; Yu-Yue Zhao; Liang Mao; Wei-Wei Deng; Tian-Fu Wu; Wen-Feng Zhang; Zhi-Jun Sun
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 4.  Advances in immunotherapy delivery from implantable and injectable biomaterials.

Authors:  David G Leach; Simon Young; Jeffrey D Hartgerink
Journal:  Acta Biomater       Date:  2019-02-13       Impact factor: 8.947

5.  Peripheral blood immune cell methylation profiles are associated with nonhematopoietic cancers.

Authors:  Devin C Koestler; Carmen J Marsit; Brock C Christensen; William Accomando; Scott M Langevin; E Andres Houseman; Heather H Nelson; Margaret R Karagas; John K Wiencke; Karl T Kelsey
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-19       Impact factor: 4.254

6.  Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer.

Authors:  Falguni Parikh; Dorothée Duluc; Naoko Imai; Amelia Clark; Krzys Misiukiewicz; Marcello Bonomi; Vishal Gupta; Alexis Patsias; Michael Parides; Elizabeth G Demicco; David Y Zhang; Seunghee Kim-Schulze; Johnny Kao; Sacha Gnjatic; Sangkon Oh; Marshall R Posner; Andrew G Sikora
Journal:  Cancer Res       Date:  2014-10-15       Impact factor: 12.701

7.  PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.

Authors:  Hyun-Bae Jie; Yu Lei; Jing Li; Neil Gildener-Leapman; Sumita Trivedi; Tony Green; Lawrence P Kane; Robert L Ferris
Journal:  Cancer Res       Date:  2014-12-05       Impact factor: 12.701

8.  Human Head and Neck Squamous Cell Carcinoma-Associated Semaphorin 4D Induces Expansion of Myeloid-Derived Suppressor Cells.

Authors:  Rania H Younis; Kyu Lee Han; Tonya J Webb
Journal:  J Immunol       Date:  2016-01-06       Impact factor: 5.422

9.  Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator.

Authors:  Aini Hyytiäinen; Rabeia Almahmoudi; Meri Sieviläinen; Anna Maria Wirsing; Priscila Rodrigues; Inger-Heidi Bjerkli; Pirjo Åström; Sanna Toppila-Salmi; Timo Paavonen; Ricardo D Coletta; Elin Hadler-Olsen; Tuula Salo; Ahmed Al-Samadi
Journal:  Head Neck Pathol       Date:  2020-09-21

10.  The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas.

Authors:  Sittichai Koontongkaew
Journal:  J Cancer       Date:  2013-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.